** Shares of Orthocell OCC.AX rise 14.3% to A$1.435, set for strongest session since January 22, if gains hold
** The biotech firm applies for a regulatory approval to begin sales of its nerve repair product Remplir in Hong Kong
** Co expects to receive approval by Q4 CY2025
** About 2.1 million shares change hands, 1.4x times the 30-day average of 1.5 million
** Stock up 5.2% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.